Revance Therapeutics

Revance Therapeutics

Developing neuromodulators for the treatment of aesthetic and therapeutic conditions
Newark United States (HQ), Newark United Kingdom

Revance Therapeutics Company information

Edit
Date
Employees
230 people
Ownership
Market cap
$1.7b
Net debt
$384m
Firm valuation
€1.2b (Public information from 2020)
USD20162017201820192020E2021E2022E
Revenues--4m3m6m98m222m
% growth---(25 %)100 %1533 %127 %
EBITDA-(119m)(141m)(162m)(225m)(189m)-
% EBITDA margin--(3525 %)(5400 %)(3750 %)(193 %)-
Profit-(121m)(143m)(159m)(255m)(216m)-
% profit margin--(3575 %)(5300 %)(4250 %)(220 %)-
EV / Revenue--153.0x1286.0x201.0x14.8x5.7x
EV / EBITDA---4.0x-3.3x-5.7x-7.6x-10.4x
  • Edit
DateInvestorsAmountRound
-N/A
N/A$25.6mSERIES D
N/A$45mSERIES D
N/A$33mSERIES E
N/A$10mEARLY VC
N/AN/AIPO
Total FundingFunding not available

Recent News about Revance Therapeutics

Edit
LocationEdit
United States, Newark

Investments by Revance Therapeutics

Edit
Are you an employee or an investor of this company?
Add your profile